… Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, … granted patent JP 7244922 , which is related to the broad concept of using chemically modified oligonucleotides …
… ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. … of ProQR and a valued member of ProQR’s Scientific Advisory Board, where he has played an important role in shaping the Company’s ADAR-based RNA editing platform. Dr. Beal’s decades of …
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.
… against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition … stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR’s intellectual …
… A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7 th Annual Genetic … am – 10:15 am EDT, and a recording of the session will be made available on the Company’s website after the conference. … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ® EONs are …
